IMMU-19. TARGETING GLIOBLASTOMA IMMUNOSUPPRESSION AND TREATMENT RESISTANCE WITH IBRUTINIB IN COMBINATION WITH STEREOTACTIC RADIATION AND IMMUNE CHECKPOINT BLOCKADE

BACKGROUND: Glioblastoma (GBM) is associated with systemic and intratumoral immunosuppression. Part of this immunosuppression is mediated by myeloid derived suppressor cells (MDSCs). Preclinical evidence shows that ibrutinib, a tyrosine kinase inhibitor FDA approved for use in chronic lymphocytic le...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Ghose, Jayeeta, Raychaudhuri, Baisakhi, Liu, Kevin, Jiang, William, Gulati, Pooja, Liu, Joseph, Rajappa, Prajwal, Ahluwalia, Manmeet, Jacob, Naduparambil, Chakravarti, Arnab, Carson, William, Raval, Raju
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Immunology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651710/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.449
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi